Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Q Lacy

Showing results (121-130 of 142) with videos related to

Pageof 15
Sort By:
Bone Marrow Transplantation|April 12, 2016
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapyW I Gonsalves, S V Rajkumar, M A Gertz, et al.
Leukemia|June 17, 2024
Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Bone Marrow Transplantation|May 4, 2010
Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilizationH V Naina, R K Pruthi, D J Inwards, et al.
Blood Cancer Journal|March 12, 2016
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Leukemia|December 17, 2015
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatmentT V Kourelis, F K Buadi, M A Gertz, et al.
Leukemia|May 22, 2021
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Blood Cancer Journal|September 2, 2017
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Bone Marrow Transplantation|September 5, 2017
A phase 1 trial of <sup>90</sup>Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myelomaA Dispenzieri, A D'Souza, M A Gertz, et al.
Leukemia Research|August 23, 2005
Ploidy status rarely changes in myeloma patients at disease progressionW J Chng, J M Winkler, P R Greipp, et al.
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
Pageof 15

Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
Bone Marrow Transplantation|April 12, 2016
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapyW I Gonsalves, S V Rajkumar, M A Gertz, et al.
Leukemia|June 17, 2024
Correction: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Bone Marrow Transplantation|May 4, 2010
Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilizationH V Naina, R K Pruthi, D J Inwards, et al.
Blood Cancer Journal|March 12, 2016
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Leukemia|December 17, 2015
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatmentT V Kourelis, F K Buadi, M A Gertz, et al.
Leukemia|May 22, 2021
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial designI Vaxman, S K Kumar, F Buadi, et al.
Blood Cancer Journal|September 2, 2017
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Bone Marrow Transplantation|September 5, 2017
A phase 1 trial of <sup>90</sup>Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myelomaA Dispenzieri, A D'Souza, M A Gertz, et al.
Leukemia Research|August 23, 2005
Ploidy status rarely changes in myeloma patients at disease progressionW J Chng, J M Winkler, P R Greipp, et al.
Blood Cancer Journal|August 15, 2015
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibS K Kumar, B LaPlant, V Roy, et al.
Pageof 15